Form 4: Acurx Pharmaceuticals Director Receives Stock Options

Director Joseph C. Scodari was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.

Summary

• Director Joseph C. Scodari received a grant of 2,150 stock options on April 20, 2026.
• The options have an exercise price of $2.36 per share.
• The options are set to vest on April 20, 2027, and expire on April 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shares upon the eventual exercise of these options.

Risks

• Market price volatility may impact the future value of the granted options.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants for board members are standard practice in the biotechnology sector to ensure director alignment with company performance and long-term strategic goals.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders due to the small number of options granted.

Next Steps

• Vesting of options on April 20, 2027.

Key Dates

Keywords

Acurx Pharmaceuticals, ACXP, Form 4, Director Compensation, Stock Options, Insider Transaction